ATE546132T1 - Prozess zur veränderung der kristallform von mycophenolat natrium salz - Google Patents

Prozess zur veränderung der kristallform von mycophenolat natrium salz

Info

Publication number
ATE546132T1
ATE546132T1 AT04703158T AT04703158T ATE546132T1 AT E546132 T1 ATE546132 T1 AT E546132T1 AT 04703158 T AT04703158 T AT 04703158T AT 04703158 T AT04703158 T AT 04703158T AT E546132 T1 ATE546132 T1 AT E546132T1
Authority
AT
Austria
Prior art keywords
changing
sodium salt
crystal form
mycophenolate sodium
mycophenolate
Prior art date
Application number
AT04703158T
Other languages
English (en)
Inventor
Sabine Pfeffer
Dierk Wieckhusen
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE546132(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE546132T1 publication Critical patent/ATE546132T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT04703158T 2003-01-20 2004-01-19 Prozess zur veränderung der kristallform von mycophenolat natrium salz ATE546132T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0301259.8A GB0301259D0 (en) 2003-01-20 2003-01-20 Organic compounds
PCT/EP2004/000354 WO2004064806A2 (en) 2003-01-20 2004-01-19 Process for modifying drug crystal formation

Publications (1)

Publication Number Publication Date
ATE546132T1 true ATE546132T1 (de) 2012-03-15

Family

ID=9951448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04703158T ATE546132T1 (de) 2003-01-20 2004-01-19 Prozess zur veränderung der kristallform von mycophenolat natrium salz

Country Status (32)

Country Link
US (3) US20060122265A1 (de)
EP (2) EP2308471A1 (de)
JP (1) JP4549976B2 (de)
KR (5) KR20070087181A (de)
CN (2) CN100595199C (de)
AR (2) AR043343A1 (de)
AT (1) ATE546132T1 (de)
AU (1) AU2004206731B2 (de)
BR (1) BRPI0406827A (de)
CA (2) CA2706900A1 (de)
CL (1) CL2004000073A1 (de)
CO (1) CO5580738A2 (de)
CY (1) CY1112772T1 (de)
DK (1) DK1592401T3 (de)
EC (1) ECSP055918A (de)
ES (1) ES2382035T3 (de)
GB (1) GB0301259D0 (de)
HK (1) HK1084874A1 (de)
IL (1) IL169484A (de)
MX (1) MXPA05007691A (de)
MY (1) MY148297A (de)
NO (1) NO20053846L (de)
NZ (1) NZ541073A (de)
PE (2) PE20040826A1 (de)
PL (2) PL376525A1 (de)
PT (1) PT1592401E (de)
RU (1) RU2388757C2 (de)
SG (1) SG155046A1 (de)
SI (1) SI1592401T1 (de)
TW (1) TWI325785B (de)
WO (1) WO2004064806A2 (de)
ZA (1) ZA200504442B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
JP2007532585A (ja) 2004-04-26 2007-11-15 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸及びそのエステル誘導体の調製方法
CA2555454C (en) 2004-04-27 2009-12-15 Sandor Molnar Mycophenolate mofetil impurity
DE602005020014D1 (de) 2004-07-20 2010-04-29 Teva Gyogyszergyar Zartkoeruen Kristallines mycophenolat-natrium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
CN102176902B (zh) * 2008-10-09 2012-10-31 阿卜迪***贸易公司 有机溶剂在莫西沙星湿法造粒中的应用
CN101756958B (zh) * 2008-11-10 2011-07-20 鲁南制药集团股份有限公司 一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
DK2451797T3 (da) 2009-07-10 2013-06-24 Janssen Pharmaceutica Nv Fremgangsmåde til krystallisation for 1-(b-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-fluorphenyl)-2- thienylmethyl]benzen
EP2488173A1 (de) * 2009-10-13 2012-08-22 Teva Pharmaceutical Industries Ltd. Zusammensetzungen mit verzögerter freisetzung
EP4148045A1 (de) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Zwischenverbindungen zur herstellung von (r)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)essigsäure und salzen davon
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
JP5973551B2 (ja) 2011-04-13 2016-08-23 ヤンセン ファーマシューティカ エヌ．ベー． Ｓｇｌｔ２の阻害物質として有用な化合物の調製プロセス
TWI582078B (zh) * 2013-01-23 2017-05-11 北京貝美拓新藥研發有限公司 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP6851379B2 (ja) * 2015-12-21 2021-03-31 ヤンセン ファーマシューティカ エヌ．ベー． カナグリフロジン半水和物結晶を得るための結晶化手順
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CN108727318A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 麦考酚酸的晶型物
CN108727317A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 一种麦考酚酸的晶型物
CN110922371B (zh) * 2019-12-27 2020-08-11 广东蓝宝制药有限公司 一种m2晶型麦考酚钠的制备方法
WO2023234158A1 (ja) * 2022-05-31 2023-12-07 本州化学工業株式会社 ４，４'－ビス（１，１－ビス（４－ヒドロキシ－３－メチルフェニル）エチル）ビフェニルの結晶及び、その製造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158835A (en) * 1875-01-19 Improvement in mortising-tools
GB935432A (en) * 1958-05-29 1963-08-28 Secr Aviation Improvements in the manufacture of crystalline substances
US3187039A (en) * 1962-10-19 1965-06-01 Commercial Solvents Corp Method for changing the crystal habit of monosodium glutamate
US3183263A (en) * 1962-10-19 1965-05-11 Commercial Solvents Corp Method for changing the crystal habit of mono-sodium glutamate
US3352906A (en) * 1963-02-04 1967-11-14 Charles R Parkerson Habit modification and preparation of single crystal triglycine sulfate
US3770390A (en) * 1971-02-26 1973-11-06 Dow Chemical Co Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) * 1980-04-21 1981-03-31 Allied Chemical Corporation Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en) 1980-06-08 1983-11-30 Yeda Res & Dev Resolution of amino acids
JPS5875194A (ja) * 1981-10-30 1983-05-06 株式会社日立製作所 マトリクス表示装置及び駆動方法
JPS59232916A (ja) * 1983-06-16 1984-12-27 Shiraishi Chuo Kenkyusho:Kk 針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物
IL77031A (en) 1985-11-12 1995-12-08 Yeda Res & Dev Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja) 1987-12-25 1995-05-17 東レ株式会社 有機化合物結晶の製造方法
DE69321531T2 (de) * 1992-08-04 1999-03-04 Toda Kogyo Corp Granulierte Teilchen für magnetische Teilchen für magnetische Aufzeichnung und Verfahren für ihre Herstellung
BR9407469A (pt) 1993-09-15 1996-11-12 Syntex Inc Micofenolato mofetil anidro cristalino e formulação intravenosa do mesmo
JPH09209297A (ja) * 1996-01-26 1997-08-12 Nippon Paper Ind Co Ltd 艶消し軽量塗工紙及びその製造方法
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
KR100491274B1 (ko) * 1996-04-12 2005-09-05 노파르티스 아게 미코페놀레이트의장용코팅된약제조성물
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
DK1592401T3 (da) 2012-05-21
ES2382035T3 (es) 2012-06-04
GB0301259D0 (en) 2003-02-19
CN101333201A (zh) 2008-12-31
IL169484A (en) 2016-03-31
WO2004064806A2 (en) 2004-08-05
PL213192B1 (pl) 2013-01-31
EP1592401B1 (de) 2012-02-22
SI1592401T1 (sl) 2012-05-31
AU2004206731A1 (en) 2004-08-05
PE20040826A1 (es) 2004-12-23
ECSP055918A (es) 2005-11-22
AR043343A1 (es) 2005-07-27
CN1738605A (zh) 2006-02-22
EP1592401A2 (de) 2005-11-09
JP2006515016A (ja) 2006-05-18
PT1592401E (pt) 2012-05-10
HK1084874A1 (en) 2006-08-11
CA2509796A1 (en) 2004-08-05
MXPA05007691A (es) 2005-09-30
SG155046A1 (en) 2009-09-30
NO20053846L (no) 2005-08-16
PL393385A1 (pl) 2011-03-14
PE20110276A1 (es) 2011-05-27
PL376525A1 (pl) 2006-01-09
AR103711A2 (es) 2017-05-31
US20060122265A1 (en) 2006-06-08
RU2005126328A (ru) 2006-07-27
RU2388757C2 (ru) 2010-05-10
CL2004000073A1 (es) 2005-01-14
US20090209639A1 (en) 2009-08-20
NZ541073A (en) 2008-12-24
KR20100120321A (ko) 2010-11-15
AU2004206731A8 (en) 2004-08-05
CA2706900A1 (en) 2004-08-05
JP4549976B2 (ja) 2010-09-22
AU2004206731B2 (en) 2008-03-20
KR20090115821A (ko) 2009-11-06
BRPI0406827A (pt) 2005-12-27
KR101129105B1 (ko) 2012-04-12
MY148297A (en) 2013-03-29
CO5580738A2 (es) 2005-11-30
US8008511B2 (en) 2011-08-30
TWI325785B (en) 2010-06-11
KR20070087181A (ko) 2007-08-27
KR20050096940A (ko) 2005-10-06
KR20090115898A (ko) 2009-11-09
CY1112772T1 (el) 2016-02-10
TW200505505A (en) 2005-02-16
US8124795B2 (en) 2012-02-28
WO2004064806A3 (en) 2004-10-28
EP2308471A1 (de) 2011-04-13
CN100595199C (zh) 2010-03-24
US20110288313A1 (en) 2011-11-24
CA2509796C (en) 2010-09-14
KR100855149B1 (ko) 2008-08-28
ZA200504442B (en) 2006-02-22
IL169484A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
ATE546132T1 (de) Prozess zur veränderung der kristallform von mycophenolat natrium salz
DE602004026576D1 (de) Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz
DE60336326D1 (de) Verfahren zur herstellung des calciumsalzes von rosuvastatin
DE602004026008D1 (de) Verfahren zur Herstellung von Flexodruckformen
DE602004032160D1 (de) Verfahren zur Zubereitung von Getränken
DE602006004463D1 (de) Kristallform von asenapinmaleat
NO20041082L (no) Fremgangsmater for fremstilling av kalsiumsaltformer av statiner
DE60209704D1 (de) Neue kristallforme von azithromycin
DE502005008502D1 (de) Vorrichtung zur veränderung der steuerzeiten von g
DE60330341D1 (de) Verfahren zur herstellung von wabenstrukturen
DE602004023529D1 (de) Regelung der Güte (Q) von Filtern
DE602004021052D1 (de) Herstellungsverfahren von Xylylendiamin
ATE286041T1 (de) Verfahren zur industriellen herstellung von 5- amino-3-carboxymethyl-4-cyano-2- thiphencarboxydimethylester
DE502004008678D1 (de) Verfahren zur Herstellung von gereinigten Elastomeren aus Lösung
DE60220554D1 (de) Mikrowelleninduzierter prozess zur herstellung von substituierten 4-vinylphenolen
FR2869030B1 (fr) Procede de production d'alpha-alumine particulaire
DE602004014217D1 (de) Verfahren für die Wiedergewinnung von Land Vorvertiefung
DE602004001646D1 (de) Verfahren zur Herstellung von Pyran
DE60232935D1 (de) Herstellungsverfahren von Druckeinheiten
DE60318444D1 (de) Verfahren zur herstellung von nevirapin
DE50310774D1 (de) Verfahren zur Regelung des Fahrverhaltens zur Vermeidung des Untersteuerns
ATE332956T1 (de) Verfahren zur senkung der viskosität von weichspülern
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
DE60218352T8 (de) Verfahren zur gewinnung von natriumarmem salz aus bitterwässern
DE502005002104D1 (de) Hesperidin zur Behandlung von Epilepsie